Evidence map›Paper›PMID 39411537›Full record

ArticleACS medicinal chemistry letters2024

Rapid Affinity and Microsomal Stability Ranking of Crude Mixture Libraries of Histone Deacetylase Inhibitors.

Sriram Tyagarajan, Christine L Andrews, Douglas C Beshore, Alexei V Buevich, Patrick J Curran, Peter Dandliker, Thomas J Greshock, Jason Hoar, Alex Kim, Prabha Karnachi and 13 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sriram TyagarajanDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Christine L AndrewsQuantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
Douglas C BeshoreDiscovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
Alexei V BuevichAnalytical Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0002-5968-9151
Patrick J CurranQuantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
Peter DandlikerQuantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
Thomas J GreshockDiscovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.ORCID https://orcid.org/0000-0002-3313-9733
Jason HoarPharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0001-7628-1759
Alex KimDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Prabha KarnachiModeling and Informatics, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Ian KnemeyerPharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
Joseph KozlowskiDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Jian LiuDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Milana MaleticDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Robert MyersDepartment of Pharmacology, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Vanessa RadaDiscovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
Deyou ShaDiscovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
Berengere SauvagnatQuantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
Petr VachalDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0002-4101-8421
Scott WolkenbergDiscovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
Wensheng YuDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Younong YuDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Shane W KrskaDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0001-9757-9036

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The science of drug discovery involves multiparameter optimization of molecular structures through iterative design-make-test cycles. For medicinal chemistry library synthesis, traditional workflows involve the isolation of each individual compound, gravimetric quantitation, and preparation of a standard concentration solution for biological assays. In this work, we explore ways to expedite this process by testing unpurified library mixtures using a combination of mass spectrometry-based assays for affinity selection and microsomal metabolic stability. Utilizing this approach, microgram quantities of crude library mixtures can be used to identify high affinity, metabolically stable library members for isolation and full characterization. This streamlined approach was demonstrated for the synthesis and evaluation of two libraries of histone deacetylase inhibitors and was shown to generate decision-making data in line with traditional workflows. The advantages of this paradigm include greatly reduced cycle time, reduced material requirements, and concentration of resources on the most promising compounds.

Identifiers

PMID39411537
PMCPMC11472384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.